Top Markets
#1 Black Phoenix Black Phoenix +355.39%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +55.09%
#4 Akedo Akedo +46.58%
#5 Acurast Acurast +34.72%
#6 BasedHype BasedHype +25.74%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.14%
#8 Avantis Avantis +22.16%
#9 Cryptopia Cryptopia +21.54%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +16.89%
Coin of the day
Black Phoenix Black Phoenix
Cài đặt
Ngôn ngữ
TIếNG VIệT
Tiền tệ
USD
Chủ đề
Immatics biotechnologies GmbH Immatics biotechnologies GmbH

Immatics biotechnologies GmbH

IMTXW
Xếp hạng trong cổ phiếu #40870
Immatics N.V. operates as a clinical-stage biopharmaceutical firm dedicated to... Immatics N.V. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T cell-redirecting immunotherapies designed to combat cancer, primarily targeting the United States market for treatment applications. Their research and development efforts are concentrated on creating targeted immunotherapies for solid tumors, employing two distinct therapeutic strategies: adoptive cell therapies (ACTs) and antibody-like T-cell receptor (TCR) Bispecifics. Immatics N.V. boasts a robust pipeline of product candidates. Among these are IMA203, an immunotherapy targeting solid tumors, and IMA203CD8, a cell therapy product, both currently undergoing Phase 1b clinical trials. Additionally, their earlier-stage assets include IMA204, designed to target tumor stroma, and IMA30x, an allogeneic cellular therapy candidate, both of which are in preclinical development. The company is also progressing with its TCR Bispecifics portfolio, featuring IMA401 in Phase 1b clinical trials, alongside IMA402 and IMA403, which are presently in preclinical phases. Furthermore, Immatics N.V. has established strategic alliances to bolster its development efforts. These include a partnership with MD Anderson Cancer Center for the advancement of various T cell and TCR-based adoptive cellular therapies, an agreement with Celgene Corporation focused on creating innovative adoptive cell therapies for diverse cancers, and a collaboration with Genmab A/S aimed at developing T cell-engaging bispecific immunotherapies for multiple oncological indications. The company's corporate headquarters are situated in Tübingen, Germany.
Giá cổ phiếu
$0.0006
Đồng bộ lần cuối: 2025-06-30
Vốn hóa thị trường
$69.91K
Thay đổi (1 ngày)
-88.46%
Thay đổi (1 năm)
0.00%
Quốc gia
US
Giao dịch Immatics biotechnologies GmbH (IMTXW)

Danh mục

Healthcare
Lịch sử giá cổ phiếu của Immatics biotechnologies GmbH (IMTXW)
Giá đóng cửa cao nhất: $0.01 vào 2025-06-01

Giá đóng cửa thấp nhất: $3.85 vào 2020-07-01
Lịch sử giá cổ phiếu của Immatics biotechnologies GmbH từ 2020 đến 2026
Hiệu suất giá cổ phiếu hàng năm
Năm Hiệu suất
2025 -95.05%
2024 -89.61%
2023 3.46%
2022 -27.40%
2021 31.37%
2020 0.00%
Giá cổ phiếu của các công ty hoặc đối thủ tương tự
Công ty Giá cổ phiếu Thay đổi 1năm% Quốc gia
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $523.45 32.21%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $863.31 33.52%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $744.96 8.94%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 $1.08K -6.68%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $259.89 16.65%
BE